attachment
attachment
attachment

Interpret

Here is a plain-language interpretation of this 3-page 18F-FDG Whole Body PET-CT second opinion report from Sir H.N. Reliance Foundation Hospital, dated 12 May 2026.

Patient Summary

Patient: Kapil Agarwal, 51-year-old male Background: Carcinoma of the left buccal mucosa (squamous cell carcinoma, confirmed on biopsy). He previously underwent:
  • Left composite resection + marginal mandibulectomy + left sentinel node biopsy with reconstruction (January 2025)
  • Radiation therapy (April 2025)
  • A prior PET-CT (January 2026) showed a new lesion along the right mandibular ramus and a spiculated lung opacity - confirmed right cheek lesion SCC on biopsy
  • Has been on chemotherapy since then
Purpose of this scan: To evaluate response to chemotherapy.

Region-by-Region Findings

Brain

  • Normal. No abnormal metabolic activity or lesions.

Head & Neck (Left Side - Operative Site)

  • Good news on the left: The surgical flap reconstruction looks stable. No abnormal FDG uptake or enhancing lesions at the operative bed - no signs of local recurrence on the treated side.
  • Left neck nodes: No significantly enlarged or FDG-avid nodes (no active nodal disease on the left).

Head & Neck (Right Side - Active Disease)

  • There is a persistent soft tissue lesion along the right mandibular ramus, infiltrating the upper right masseter muscle.
  • Size reduced: From 3.6 x 2.6 x 3.1 cm → now 3.2 x 2.3 x 2.6 cm
  • SUVmax reduced: From 8.2 → now 7.1 (SUVmax reflects metabolic activity; lower = less active)
  • The lesion still erodes the right zygomatic bone cranially, but no significant destruction of the mandibular ramus itself.
  • It has effaced fat planes near the right parotid gland and infiltrates the subcutaneous space, but the overlying skin appears uninvolved.
  • Small right neck level IB, II, and tiny level III nodes show low-grade FDG uptake - considered likely reactive (not malignant) and are stable.

Thorax (Lungs)

  • A persistent spiculated opacity (irregular lung mass) in the right lung perihilar region, abutting the right pulmonary artery (middle/lower lobe branches).
  • Size reduced: From 2.8 x 2.4 x 2.5 cm → now 2.3 x 1.6 x 2.5 cm
  • SUVmax: 6.14 (previously 6.4) - marginally reduced metabolic activity
  • Causing compression of right middle lobe bronchi with some distal collapse (atelectasis).
  • No pleural effusion. No other lung lesions. No enlarged mediastinal or axillary nodes.

Abdomen & Pelvis

  • Liver, spleen, gallbladder, pancreas, adrenals, left kidney: All normal.
  • Tiny calcium deposit in the right kidney (incidental, likely benign).
  • Prostate is mildly enlarged but shows no suspicious FDG uptake.
  • No abnormal nodes in the abdomen or pelvis.

Musculoskeletal / Bones

  • No FDG-avid lytic or sclerotic bone metastases anywhere in the body.

Overall Conclusion (Radiologist's Remarks)

The report concludes:
"Overall scan findings are suggestive of partial response to treatment."
In plain terms, this means:
  1. The right mandibular/masseter lesion has shrunk slightly and become slightly less metabolically active, but it is still present and still active (SUVmax 7.1 is significantly elevated).
  2. The right lung lesion has also partially reduced in size but remains active.
  3. The left-side surgical site is clean - no recurrence there.
  4. No new metastatic sites have appeared anywhere in the body.

What "Partial Response" Means Clinically

In oncology response criteria (e.g., RECIST or PERCIST):
  • Complete response = no detectable disease
  • Partial response = measurable reduction in tumor size/activity (typically >30% reduction in size), but disease is still present
  • Stable disease = no significant change
  • Progressive disease = tumor growth or new lesions
This patient falls into partial response - chemotherapy is working to some degree, but the disease has not been eliminated. The treating oncologist will need to decide whether to continue the same regimen, intensify it, switch to a different regimen, or consider other interventions (such as surgery or radiation to the residual sites).

Important note: This interpretation is for informational purposes only. Treatment decisions should be made by the patient's oncology team, who have the full clinical context.
This is a shared conversation. Sign in to Orris to start your own chat.